Latest developmentabout 2 hours ago
Bayer AG Raises Cash Flow Forecast and Sets New Debt Reduction Targets
Bayer AG strengthens its financial outlook and updates 2026 debt targets following a significant transaction with Apollo.
Read the full story
Bayer raised its full-year guidance after third-quarter sales and EBITDA grew, led by its pharmaceutical division. Revenue was $11.3 billion, above the $11.2 billion estimate, but down 14.9% from $13.2 billion a year earlier; EPS was $0.11 versus the $0.13 estimate. Impairments and legal-settlement payments reduced net income and free cash flow, while net debt declined. On Nov. 5, Bayer raised its year-end cash flow forecast and updated its debt-reduction targets, supported by a significant transaction with Apollo.
Bayer AG strengthens its financial outlook and updates 2026 debt targets following a significant transaction with Apollo.
Read the full storyThe results cover the company's Q3 FY2026. EPS came in below analysts' estimate by 15.4%; revenue above the estimate by 0.4%.
The pharmaceuticals division led the improvement in results, while the company raised its free cash flow forecast and lowered its debt outlook, despite posting a net loss and facing pressure in Crop Science.